Table 2.
Variable | uHR age >50 years (95% CI) | p | aHR age >50 years (95% CI) | p | uHR age 15 to 50 years (95% CI) | p | aHR age 15 to 50 years (95% CI) | p |
---|---|---|---|---|---|---|---|---|
Gender | ||||||||
Male | 1 | 1 | 1 | 1 | ||||
Female | 0.71 (0.58, 0.88) | <0.01 | 0.73 (0.59, 0.90) | <0.01 | 0.64 (0.60, 0.69) | <0.01 | 0.70 (0.66, 0.75) | <0.01 |
CD4 count | ||||||||
<200 | 1 | 1 | 1 | 1 | ||||
200 to 499 | 0.65 (0.46, 0.94) | 0.02 | 0.72 (0.50, 1.03) | 0.07 | 0.46 (0.41, 0.52) | <0.01 | 0.58 (0.52, 0.66) | <0.01 |
≥500 | 0.51 (0.16, 1.61) | 0.25 | 0.81 (0.25, 2.56) | 0.71 | 0.25 (0.15, 0.40) | <0.01 | 0.29 (0.18, 0.47) | <0.01 |
Missing | 1.01 (0.81, 1.25) | 0.96 | 0.91 (0.72, 1.14) | 0.42 | 1.05 (0.98, 1.12) | 0.20 | 1.00 (0.93, 1.07) | 1 |
WHO stage | ||||||||
1 | 1 | 1 | 1 | 1 | ||||
2 | 1.16 (0.61, 2.22) | 0.64 | 1.22 (0.64 to 2.33) | 0.55 | 1.06 (0.81, 1.38) | 0.67 | 0.94 (0.72, 1.23) | 0.67 |
3 | 1.68 (0.98, 2.89) | 0.06 | 1.51 (0.87, 2.62) | 0.14 | 2.70 (2.21, 3.29) | <0.01 | 2.21 (1.81 to 2.71) | <0.01 |
4 | 2.44 (1.40, 4.23) | <0.01 | 1.93 (1.10 to 3.39) | 0.02 | 5.33 (4.36, 6.50) | <0.001 | 3.99 (3.26, 4.88) | <0.01 |
BMI | ||||||||
<18.5 | 1 | 1 | 1 | 1 | ||||
18.5 to 25 | 0.45 (0.34, 0.59) | <0.01 | 0.49 (0.37, 0.65) | <0.01 | 0.45 (0.41, 0.49) | <0.01 | 0.55 (0.50, 0.60) | <0.01 |
>25 | 0.20 (0.08, 0.48) | <0.01 | 0.20 (0.07, 0.54) | 0.02 | 0.33 (0.25, 0.45) | <0.01 | 0.55 (0.41 to 0.73) | <0.01 |
Missing | 1.21 (0.96, 1.52) | 0.11 | 1.32 (1.04, 1.68) | 0.03 | 1.31 (1.22, 1.41) | <0.01 | 1.48 (1.37, 1.59) | <0.01 |
Region | ||||||||
Africa | 1 | 1 | 1 | 1 | ||||
Asia | 1.16 (0.91, 1.47) | 0.22 | 1.1 (0.87, 1.41) | 0.43 | 0.77 (0.71, 0.83) | <0.01 | 0.64 (0.59.0.69) | <0.01 |
Europe | – | – | – | – | 1.03 (0.66, 1.63) | 0.89 | 1.87 (1.18, 2.96) | <0.01 |
uHR, unadjusted hazard ratio; aHR, adjusted hazard ratio; BMI, body mass index; CI, confidence interval; ART, antiretroviral therapy. Values in bold values indicate those that reached statistical significance (p<0.05).